Möchten Sie immer auf dem neuesten Stand bleiben?

Lausanne, Switzerland, July 6, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the...

Announced first-in-human study for an alpha-synuclein PET tracer for Parkinson's disease Selected Tau small molecules (Tau Morphomers) have entered into IND/CTA* enabling studies; Phase 1 to...

Lausanne, Switzerland, April 27, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the...

Tau small molecules (Tau Morphomers) demonstrate target-specific reduction of pathological Tau as well as cognitive and functional improvement Significant reduction of microglia activation...

Lausanne, Switzerland, March 20, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...

First potential PET tracer for Parkinson's disease First in human study is scheduled for the second half of 2018 AC Immune's lead compound is highly selective for alpha-synuclein - a key protein...

Lausanne, Switzerland, - February 6, 2018 -   AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...

Lausanne, Switzerland,  December 1, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, shared...

Lausanne, Switzerland, November 21, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...

Expansion of pipeline with two new antibodies against proteins alpha-synuclein and TDP-43 Recruitment of first cohort completed for anti-beta vaccine targeting Alzheimer's symptoms in adults...